---
schema_version: "secwatch.filing_event.v1"
accession: "0000012208-23-000045"
form_type: "8-K"
ticker: "BIO"
cik: "0000012208"
company_name: "BIO-RAD LABORATORIES, INC."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T20:43:52.067062+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bio-Rad Q1 sales down 3.3% to $676.8M; operating income drops 57.7% to $61.9M

## Summary
- Net sales $676.8M, down 3.3%; currency-neutral down 0.3%; ex-COVID up 6.1%.
- GAAP diluted EPS $2.32 vs loss of $112.50; operating income $61.9M vs $146.4M.
- Life Science sales $323.6M, down 6.8% (ex-COVID up 9.6% on qPCR, western blotting, ddPCR).
- Clinical Diagnostics sales $352.1M flat; currency-neutral up 2.8% ex-COVID up 3.1%.
- COVID sales dropped to $2.6M from $45M; gross margin fell to 53.5% from 57.5%.

## SEC filing metadata
- accession: 0000012208-23-000045
- form_type: 8-K
- ticker: BIO
- cik: 0000012208
- company_name: BIO-RAD LABORATORIES, INC.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/12208/000001220823000045/0000012208-23-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/12208/000001220823000045/bio-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000012208-23-000045
- JSON: https://secwatch.observer/filing/0000012208-23-000045.json
- Plain text: https://secwatch.observer/filing/0000012208-23-000045.txt

## Key facts
- Earnings Releases
  BIO-RAD LABORATORIES, INC. reported the first quarter ended March 31, 2023 results: revenue $676.8 million, net income $69 million, EPS $2.32 per diluted share.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $676.8 million
  - Net income: $69 million
  - EPS: $2.32 per diluted share
  - Result: reported results
  source text: First-quarter 2023 net sales were $676.8 million, a decrease of 3.3 percent compared to $700.1 million reported for the first quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/12208/000001220823000045/0000012208-23-000045-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.